Compare Incyte Corporation (INCY) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Utilities Select Sector SPDR Fund — how do they compare? Incyte Corporation trades at $113.37 (market cap $22.85B), while Utilities Select Sector SPDR Fund trades at $41.41 (market cap $23.60B). The key difference: Incyte Corporation and Utilities Select Sector SPDR Fund are close in size by market cap, and Incyte Corporation is trading nearer its 52-week high, Utilities Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Utilities Select Sector SPDR Fund for 80 Days on average.
| INCY | XLU | |
|---|---|---|
Market Cap | $22.85B | $23.60B |
Volume | 1,927,029 | 28,758,237 |
Sector | Health | — |
52-Week High | $129.93 | $47.73 |
52-Week Low | $83.80 | $39.25 |
Typical Hold Time | 33 Days | 80 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
XLU trades at $41.35, up 0.49% with a mixed technical signal showing bullish moving averages but neutral oscillators. The ETF recently hit 52-week lows amid utility sector pressure from rising interest rates. Support levels cluster around $40-41 with resistance at $42. Recent news highlights oversold conditions and defensive positioning opportunities.
The outlook remains cautious with interest rate sensitivity being the primary risk. Defensive characteristics may appeal during market volatility, but sector headwinds from AI power demand shifts and regulatory challenges require monitoring. Current technical positioning suggests near-term consolidation around current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
